# Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

> **NCT05540665** · PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 19 (actual)

## Conditions studied

- Lupus Nephritis

## Interventions

- **DRUG:** Daxdilimab
- **DRUG:** Daxdilimab
- **DRUG:** Placebo (Normal Saline)

## Key facts

- **NCT ID:** NCT05540665
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-26
- **Primary completion:** 2024-01-04
- **Final completion:** 2024-01-04
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05540665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05540665, "Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05540665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*